Integra LifeSciences receives ‘buy’ rating — 4 notes

Bank of America analysts upgraded Integra LifeSciences stock from a ”neutral” rating to a ‘buy” rating, according to WKRB.

Advertisement

Here are four notes:

 

1. The companys shares traded down 0.38 percent on Mon., Sept. 21.

 

2. Integra LifeSciences has a 12-month low of $42.09 and a 12-month high of $68.46.

 

3. The stock has a 50-day moving average of $62.13 and a 200-day moving average of $60.04.

 

4. The market cap is $2.17 billion and P/E ratio is 53.91.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in Orthopedic

Advertisement

Comments are closed.